Search

Displaying results 3701 - 3710 of 5449 in total
  1. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. … It is currently being studied for post-ischemic stroke management [L1380].

  2. Drug

    Vancomycin

    go.drugbank.com/drugs/DB00512
    ApprovedInvestigational

    It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

    Products: VANCOMICINA BONISCONTRO E GAZZONE, VANEOTIK® 125 MG
  3. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    It was first approved by the FDA on August 27, 2018 [L4540].

  4. Drug

    Sepiapterin

    go.drugbank.com/drugs/DB16326
    ApprovedInvestigational

    It is a natural precursor of the enzymatic co-factor tetrahydrobiopterin (BH4), which activates PAH and helps reduce blood phenylalanine levels by enhancing the conformational stability of misfolded PAH

  5. Drug

    Samarium (153Sm) lexidronam

    go.drugbank.com/drugs/DB05273
    Approved

    It is a radiopharmaceutical.

    Products: T-BONE KAEF
  6. Drug

    Human varicella-zoster immune globulin

    go.drugbank.com/drugs/DB11621
    ApprovedInvestigational

    It is prepared from pools of healthy human donors' plasma via anion-exchange column chromatography and was approved in 2012 under the name VariZIG to reduce the disease severity in high-risk patients who

  7. Drug

    Lutropin alfa

    go.drugbank.com/drugs/DB00044
    ApprovedInvestigational

    It is a heterodimeric glycoprotein made up of monomeric units.

  8. Drug

    Inotersen

    go.drugbank.com/drugs/DB14713
    ApprovedInvestigational

    It was FDA approved in October 2018.

  9. Drug

    Bavituximab

    go.drugbank.com/drugs/DB05136
    Investigational

    It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.

  10. Drug

    GW 468816

    go.drugbank.com/drugs/DB05417
    Investigational

    It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.